期刊文献+

帕利哌酮缓释片与奥氮平对精神分裂症患者生活质量的影响 被引量:1

Comparative study on influence of Paliperidone extended-release tablet and Olanzapine on quality of life in schizophrenia
下载PDF
导出
摘要 目的:比较帕利哌酮缓释片与奥氮平对精神分裂症患者的疗效及生活质量的影响。方法:将62例精神分裂症患者,随机分为帕利哌酮缓释片组(31例)和奥氮平组(31例)治疗,疗程12周。分别于治疗前与治疗4、8、12周末,应用阴性与阳性症状量表(PANSS)评定疗效,用副反应量表(TESS)评定治疗过程中出现的不良反应,于治疗前和12周末采用生活质量综合评定问卷(GQOLI-74)评定生活质量。结果:两组均有显著疗效,帕利哌酮缓释片组与奥氮平组均可显著提高生活质量(P均<0.01);两组比较无显著性差异(P>0.05)。帕利哌酮缓释片的主要不良反应是锥体外系反应及嗜睡,奥氮平组在体重增加及血糖升高方面与帕利哌酮缓释片组比较有显著性差异(P<0.01)。结论:帕利哌酮缓释片与奥氮平对精神分裂症疗效好,不良反应少,均可提高患者的生活质量。 Objective:To investigate the efficacy and quality of life in schizophrenic patients treated by Paliperidone extended -release tablet and Olanzapine. nethods:A total of 62 patients with schizophrenia were randomly divided into Paliperidone extended -release tablet group and Olanzapine group for 12 -week treatment. Positive and Negative Symptoms Scale (PANSS) was used to e- valuate the clinical efficacy, Treatment Emergent Symptom Scale (TESS) for side effects and General Quality of Life Inventory (GQO- LI - 74 ) for quality of life. Results : The patients in both groups had significant clinical efficacy, and the two drugs obviously improved the quality of life. There were no significant differences in the efficacy and quality of life ( P 〉 0.05 ) between the two groups. The side effects of Paliperidone extended - release tablet were extra pyramidal reactions and drowsiness , and those of Olanzapine were weightgain and increased blood glucose. Conclusions: Paliperidone extended - release tablet and Olanzapine are similar an the treatment ol schizophrenia with fewer side effects , and they both improve quality of life.
出处 《中国民康医学》 2012年第13期1546-1548,共3页 Medical Journal of Chinese People’s Health
关键词 帕利哌酮缓释片 奥氮平 精神分裂症 生活质量 Paliperidone extended-release tablet Olanzapine Schizophrenia Quality of life
  • 相关文献

参考文献15

  • 1Moiler HJ. Gradually improving treatment from the traditional oral neuroleptics to the frst atypical depot paychiatry[J].Eur Antipsy- chotic Agents ,2005,20:379 - 385.
  • 2Lublin H, Eberhard J,Levander S. Current therapy issues and un- met clinical needs in the treatment of schizophrenia:areview of the- new generation antipsychotics [ J ]. Int Clin Psychopharmacol, 2005,20 : 183 - 198.
  • 3Lindenmayer JP, Khan A. Pharmacological treatment strategies for schizophrenia[ J]. Expert Rew Neurother, 2004,4 : 705 - 723.
  • 4Davis JM, Chen N. Clinical profile of an atypical antipsychotie : fis- peridone [ J ]. Schizophr Bu11,2002,28:43 - 61.
  • 5Leucht S, Barnes TR, Kissing W, et al. Relapse prevention in schiz- ophrenia with new - generation antipsychotics : a systematic review and exploratory meta - analysis of randomized, controlled trials [ J ]. Am J Psychiatry,2003,160 : 1209 - 1222.
  • 6贾福军,侯彩兰.帕利哌酮缓释片改善精神分裂症患者社会功能的探讨[J].中华精神科杂志,2010,43(3):180-182. 被引量:25
  • 7中华医学会精神科分会.中国精神障碍分类与诊断标准[M].第三版.济南:山东科学技术出版社,2001:62-75.
  • 8李凌江,杨德森.生活质最综合评定问卷-74(GQOLI-74)[J].中国行为医学科学,2001,10(特刊):74-81.
  • 9张鸿燕,李华芳,王刚,李婷,谢世平,肖卫东,谭庆荣,舒良.帕利哌酮缓释片治疗急性精神分裂症疗效及安全性的对照研究[J].中华精神科杂志,2009,42(3):153-157. 被引量:29
  • 10余一旻,李华芳,杨甫德,胡建,赵振环,董继承,陈红辉,许秀峰,李鸣,王刚,王晓萍,谢世平,唐济生,张晋碚,关念红,丁瑛,谭庆荣,李惠春,钟华,张鸿燕,谢光荣,孙学礼,顾牛范.可变剂量帕利哌酮缓释剂治疗急性期精神分裂症的疗效、耐受性及安全性[J].上海精神医学,2010,22(6):349-353. 被引量:17

二级参考文献73

  • 1Moiler ILl. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot psychiatry. Eur Antipsychotic Agents ,2005, 20:379-385.
  • 2Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol, 2005, 20 : 183-198.
  • 3Lindenmayer JP, Khan A. Pharmacological treatment strategies for schizophrenia. Expert Bey Neurother, 2004, 4:705-723.
  • 4Davis JM, Chen N. Clinical profile of an atypical antipsychofic: risperidone. Schizophr Bull, 2002, 28:43-61.
  • 5Marder SR, Davis JM, Chouinard G. The effects of rispefidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry, 1997, 58:538-546.
  • 6Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curt Med Res Opin, 2006, 22 : 1879-1892.
  • 7Gharabawi GM, Bossie CA. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS) : cross-scale comparison in assessing tardive dyskinesia. Schizophr Res, 2005, 77 : 119-128.
  • 8Barnes TR. The Barnes Akathisia Rating Scale-revisited. J Psychopharmacol, 2003,17:365-370.
  • 9Janno S, Holi MM, Tuisku K, et al. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol, 2005, 5:5-10.
  • 10Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebocontrolled trial. Schizophr Res, 2007, 90 : 147-161.

共引文献169

同被引文献7

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部